Gyros Expands Asian Distribution to Singapore
News Jun 07, 2012
Gyros AB has announced that Bio Laboratories Pte Ltd (www.biolab.com.sg) has become sole distributor for the company’s nanoliter-scale immunoassay platform in Singapore.
The Gyros platform (www.gyros.com) is used by major biopharmaceutical companies and their service providers worldwide to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.
“We are very pleased to expand our reach in Asia through this new partnership with Bio Laboratories, which provides a valuable addition to our recently announced collaboration with GE Healthcare for distribution in Japan, China, Taiwan and Hong Kong,” commented Erik Walldén, CEO, Gyros.
Walldén continued, “As our immunoassay platform increases in acceptance within the biopharmaceutical industry, it is ever more vital that we have an experienced and respected network of distributors to ensure the highest possible standards of service and support for our customers.”
Benny Wee, Managing Director, Bio Laboratories, said, “The Gyros immunoassay platform is an excellent addition to our extensive range of distribution agreements with high quality, innovative analytical instrument providers. We are delighted to be able to now offer Gyros’ products to the biopharmaceutical industry in Singapore.”
Nanoantenna Arrays That Could Aid Water Quality MonitoringNews
Researchers have designed and tested a series of plasmonic nanoantenna arrays that could lead to the development of a new generation of ultrasensitive and low-cost fluorescence sensors that could be used to monitor water quality.READ MORE
Gilead Company Wins FDA Approval for CAR T Cancer Therapy for Treatment of Adult LymphomaNews
Kite’s Yescarta™ (axicabtagene ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.READ MORE